{"id":381657,"date":"2020-11-16T08:03:47","date_gmt":"2020-11-16T13:03:47","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381657"},"modified":"2020-11-16T08:03:47","modified_gmt":"2020-11-16T13:03:47","slug":"pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/","title":{"rendered":"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

DAEJEON,\u00a0South Korea, Nov. 16, 2020<\/span> \/PRNewswire\/ — PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO\u00a0(Society of Neuro-Oncology) 2020.<\/p>\n

\n

\n
\n \"PharmAbcineLogo
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n The<\/span> clinical study was conducted in Australia<\/span>from<\/span> 2016- 2017. \u00a0In the study,<\/span> 25% of the patients had stable disease and 40% of the patients had relief<\/span> from brain edema. The data from the study suggested the<\/span>\u00a0possibility of using Olinvacimab for rGBM patients who no longer respond to Avastin in treating severe brain edema.<\/p>\n

In 2017, PharmAbcine received approval<\/span> from the<\/span> US FDA (Food and Drug Administration) for the Phase II clinical study of Olinvacimab for Avastin-refractory rGBM patients. Furthermore, Olinvacimab received Orphan Drug Designation (ODD) from both the US FDA and the Korean MFSD (Ministry of Food and Drug Safety) in 2018. Beginning<\/span> in 2019, the Phase II clinical trial is currently on-going.<\/p>\n

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor with a fast growth rate. Recurrent glioblastoma multiforme (rGBM) is a disease in which the GBM recur after surgery and drug\/radiation therapy. It is known that rGBM has an<\/span> average life expectancy of about 4 months and causes extensive brain edema.<\/p>\n

\n About Society of Neuro-Oncology Annual Meeting<\/b>\n <\/p>\n

Society of Neuro-Oncology Annual Meeting is the world’s largest neuro-oncology society held every year. This year marks 25<\/span>th<\/sup> event with more than 2600 researchers and experts participating from more than 40 countries around the world. Through this event, many global pharmaceutical companies will present various cutting-edge technologies and advance their academic and research efforts in the field of neuro-oncology. SNO 2020 will be held virtually from\u00a0November 19\u00a0to 21.<\/p>\n

\n About PharmAbcine Inc.<\/b>\n <\/p>\n

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from\u00a0oncology, immuno-oncology, ophthalmology, respiratory, to renal pathology.<\/p>\n

PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine’s advanced 3G expression system\u00a0accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state of the art antibody generation services. <\/p>\n

For additional information about PharmAbcine, visit\u00a0http:\/\/www.pharmabcine.com<\/a>. <\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020-301172595.html<\/a><\/p>\n

SOURCE PharmAbcine<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire DAEJEON,\u00a0South Korea, Nov. 16, 2020 \/PRNewswire\/ — PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO\u00a0(Society of Neuro-Oncology) 2020. The clinical study was conducted in Australiafrom 2016- 2017. \u00a0In the study, 25% of the patients had stable disease and 40% of the patients had relief from brain edema. The data from the study suggested the\u00a0possibility of using Olinvacimab for rGBM patients who no longer respond to Avastin in treating severe brain edema. In 2017, PharmAbcine received approval from the US FDA (Food and Drug Administration) for the Phase II clinical study of Olinvacimab for Avastin-refractory rGBM patients. … <\/p>\n

Continue reading “PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-381657","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire DAEJEON,\u00a0South Korea, Nov. 16, 2020 \/PRNewswire\/ — PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO\u00a0(Society of Neuro-Oncology) 2020. The clinical study was conducted in Australiafrom 2016- 2017. \u00a0In the study, 25% of the patients had stable disease and 40% of the patients had relief from brain edema. The data from the study suggested the\u00a0possibility of using Olinvacimab for rGBM patients who no longer respond to Avastin in treating severe brain edema. In 2017, PharmAbcine received approval from the US FDA (Food and Drug Administration) for the Phase II clinical study of Olinvacimab for Avastin-refractory rGBM patients. … Continue reading "PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T13:03:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020\",\"datePublished\":\"2020-11-16T13:03:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/\"},\"wordCount\":397,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1176198\\\/PharmAbcineLogo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/\",\"name\":\"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1176198\\\/PharmAbcineLogo.jpg\",\"datePublished\":\"2020-11-16T13:03:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1176198\\\/PharmAbcineLogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1176198\\\/PharmAbcineLogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/","og_locale":"en_US","og_type":"article","og_title":"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 - Market Newsdesk","og_description":"PR Newswire DAEJEON,\u00a0South Korea, Nov. 16, 2020 \/PRNewswire\/ — PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO\u00a0(Society of Neuro-Oncology) 2020. The clinical study was conducted in Australiafrom 2016- 2017. \u00a0In the study, 25% of the patients had stable disease and 40% of the patients had relief from brain edema. The data from the study suggested the\u00a0possibility of using Olinvacimab for rGBM patients who no longer respond to Avastin in treating severe brain edema. In 2017, PharmAbcine received approval from the US FDA (Food and Drug Administration) for the Phase II clinical study of Olinvacimab for Avastin-refractory rGBM patients. … Continue reading \"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T13:03:47+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020","datePublished":"2020-11-16T13:03:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/"},"wordCount":397,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/","name":"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg","datePublished":"2020-11-16T13:03:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=381657"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381657\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=381657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=381657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=381657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}